PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
A recent study led by UC Davis Health researchers provides new insights into the molecular changes linked to the rare genetic condition 22q11.2 deletion syndrome, or 22q. It found unique biomarkers ...
A team of researchers led by Professor Yoko Hamazaki and Assistant Professor Yann Pretemer (Department of Life Science Frontiers) has developed an in vitro model that faithfully recapitulates human ...
Down syndrome is an easily recognized, well-known genetic disorder. But there is another genetic disorder that even more babies are born with and it is rarely talked about. It is called 22q11.2 ...
DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals (ZYNE), Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...
Zynerba Pharmaceuticals, Inc. ZYNE presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. The data were ...
A team of researchers led by Professor Yoko Hamazaki and Assistant Professor Yann Pretemer (Department of Life Science Frontiers) has developed an in vitro model that faithfully recapitulates human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results